Maria Pia Riccio

Dr. Maria Pia Riccio

UOSD Child Neuropsychiatry, University Federico II of Naples, Naples, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
LCLorena Coretti
Lorena Coretti
LPLorella Paparo
Lorella Paparo
MRMaria Pia Riccio
Maria Pia Riccio
FAFelice Amato
Felice Amato
Mariella CuomoMariella Cuomo
Mariella Cuomo
FLFrancesca Lembo
Francesca Lembo
Proliferation and/or depletion of clusters of specific bacteria regulate intestinal functions and may interfere with neuro-immune communication and behavior in patients with autism spectrum disorder (ASD). Consistently, qualitative and quantitative alteration of bacterial metabolites may functionally affect ASD pathophysiology. Up to date, age-restricted cohort studies, that may potentially help to identify specific microbial signatures in ASD, are lacking. We investigated the gut microbiota (GM) structure and fecal short chain fatty acids (SCFAs) levels in a cohort of young children (2–4 years of age) with ASD, with respect to age-matched neurotypical healthy controls. Strong increase of Bacteroidetes and Proteobacteria and decrease of Actinobacteria was observed in these patients. Among the 91 OTUs whose relative abundance was altered in ASD patients, we observed a striking depletion of Bifidobacterium longum, one of the dominant bacteria in infant GM and, conversely, an increase of Faecalibacterium prausnitzii, a late colonizer of healthy human gut and a major butyrate producer. High levels of F. prausnitzii were associated to increase of fecal butyrate levels within normal range, and over representation of KEGG functions related to butyrate production in ASD patients. Here we report unbalance of GM structure with a shift in colonization by gut beneficial bacterial species in ASD patients as off early childhood.

8 February 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Leonardo Emberti GialloretiLeonardo Emberti Gialloreti
Leonardo Emberti Gialloreti
LMLuigi Mazzone
Luigi Mazzone
ABArianna Benvenuto
Arianna Benvenuto
Alessio FasanoAlessio Fasano
Alessio Fasano
AGAlicia García-Alcón
Alicia García-Alcón
PCPaolo Curatolo
Paolo Curatolo
Autism Spectrum Disorder (ASD) is a complex condition with early childhood onset, characterized by a set of common behavioral features. The etiology of ASD is not yet fully understood; however, it reflects the interaction between genetics and environment. While genetics is now a well-established risk factor, several data support a contribution of the environment as well. This paper summarizes the conclusions of a consensus conference focused on the potential pathogenetic role of environmental factors and on their interactions with genetics. Several environmental factors have been discussed in terms of ASD risk, namely advanced parental age, assisted reproductive technologies, nutritional factors, maternal infections and diseases, environmental chemicals and toxicants, and medications, as well as some other conditions. The analysis focused on their specific impact on three biologically relevant time windows for brain development: the periconception, prenatal, and early postnatal periods. Possible protective factors that might prevent or modify an ASD trajectory have been explored as well. Recommendations for clinicians to reduce ASD risk or its severity have been proposed. Developments in molecular biology and big data approaches, which are able to assess a large number of coexisting factors, are offering new opportunities to disentangle the gene–environment interplay that can lead to the development of ASD.

6 October 2015 in Autism Research
Verified
Journal Article
Closed access
PDF file
SGStefano Gabriele
Stefano Gabriele
RSRoberto Sacco
Roberto Sacco
LALaura Altieri
Laura Altieri
CNCristina Neri
Cristina Neri
AUAndrea Urbani
Andrea Urbani
APAntonio M. Persico
Antonio M. Persico

1 January 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
LMLaura de Magistris
Laura de Magistris
APAnnarita Picardi
Annarita Picardi
Dario SiniscalcoDario Siniscalco
Dario Siniscalco
MRMaria Pia Riccio
Maria Pia Riccio
ASAnna Sapone
Anna Sapone
CBCarmela Bravaccio
Carmela Bravaccio
Purpose. Immune system of some autistic patients could be abnormally triggered by gluten/casein assumption. The prevalence of antibodies to gliadin and milk proteins in autistic children with paired/impaired intestinal permeability and under dietary regimen either regular or restricted is reported.Methods. 162 ASDs and 44 healthy children were investigated for intestinal permeability, tissue-transglutaminase (tTG), anti-endomysium antibodies (EMA)-IgA, and total mucosal IgA to exclude celiac disease; HLA-DQ2/-DQ8 haplotypes; total systemic antibodies (IgA, IgG, and IgE); specific systemic antibodies:α-gliadin (AGA-IgA and IgG), deamidated–gliadin-peptide (DGP-IgA and IgG), total specific gliadin IgG (all fractions:α,β,γ, andω),β-lactoglobulin IgG,α-lactalbumin IgG, casein IgG; and milk IgE, casein IgE, gluten IgE, -lactoglobulin IgE, andα-lactalbumin IgE.Results. AGA-IgG and DPG-IgG titers resulted to be higher in ASDs compared to controls and are only partially influenced by diet regimen. Casein IgG titers resulted to be more frequently and significantly higher in ASDs than in controls. Intestinal permeability was increased in 25.6% of ASDs compared to 2.3% of healthy children. Systemic antibodies production was not influenced by paired/impaired intestinal permeability.Conclusions. Immune system of a subgroup of ASDs is triggered by gluten and casein; this could be related either to AGA, DPG, and Casein IgG elevated production or to impaired intestinal barrier function.

21 May 2016 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
SPSimone Pisano
Simone Pisano
GCGennaro Catone
Gennaro Catone
SVStefania Veltri
Stefania Veltri
VLValentina Lanzara
Valentina Lanzara
MPMarco Pozzi
Marco Pozzi
GMGabriele Masi
Gabriele Masi
During the past decade, a substantial increase in the use of second generation antipsychotics (SGAs) has occurred for a number of juvenile psychiatric disorders, often as off-label prescriptions. Although they were thought to be safer than older, first generation antipsychotics, mainly due to a lower risk of neurological adverse reactions, recent studies have raised significant concerns regarding their safety regarding metabolic, endocrinological and cardiovascular side effects. Aim of this paper is to update with a narrative review, the latest findings on safety of SGAs in youths. Results suggest that different SGAs may present different safety profiles. Metabolic adverse events are the most frequent and troublesome, with increasing evidences of heightened risk for type II diabetes mellitus. Results are discussed with specific emphasis on possible strategies of an active monitoring, which could enable both paediatricians and child psychiatrists to a possible prevention, early detection, and a timely management of such effects.

28 December 2017 in Autism Research
Verified
Journal Article
Closed access
PDF file
MRMaria Pia Riccio
Maria Pia Riccio
CFChiara Franco
Chiara Franco
RNRossella Negri
Rossella Negri
RFRoberta Ida Ferrentino
Roberta Ida Ferrentino
RMRoberta Maresca
Roberta Maresca
CBCarmela Bravaccio
Carmela Bravaccio